F32.0 F32.1 F32.2 F32.8 F32.9 F33.0 F33.1 F33.2 F33.8 F33.9 F34.1
Conditions
Interventions
Group 1: Intervention group = receives access to the internet-based support program Novego - "Depressionen bewältigen"®
Group 2: Waiting control group = receives no additional treatment during the int
receives access to the intervention after 12 weeks (after post-survey)
Sponsors
IVP Networks GmbH
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: • one of the following diagnoses according to ICD-10 made by specialists or psychotherapists: F32.0, F32.1, F32.2, F32.8, F32.9, F33.0, F33.1, F33.2, F33.8, F33.9, F34.1 • A sum score on the PHQ-9 at the time of the baseline interview of at least 5 (at least mild expression of depression) • informed consent • access to the Internet • sufficient knowledge of the German language • willingness to participate in three anonymous online surveys and willingness to independently use Novego - "Depressionen bewältigen"®. • Patients must be in a stable therapy situation (pharmacotherapy and/or psychotherapy or waiting situation) at least 4 weeks before randomization and should maintain this situation as far as possible during the study period.
Exclusion criteria
Exclusion criteria: • the presence of a psychotic or bipolar disorder (lifetime) • acute suicidal behavior within the last 4 weeks • dementia • alcohol or substance dependence within the last 6 months • current use of antipsychotics • Presence of a serious illness which, in the opinion of the investigator, precludes the patient's participation in the study until the end of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in depressive symptomatology (sum score) at T2 compared to T0, as measured by the Beck Depression Inventory-II (BDI-II; Beck, Steer, & Brown, 1996) | — |
Secondary
| Measure | Time frame |
|---|---|
| • Reduction in depressive symptomatology (sum score) at T2 compared to T0, as measured by the PHQ-9 (Gräfe et al., 2004; Kroenke et al., 2001) • Increase in quality of life (mean score) at T2 compared to T0, as measured by the WHO-QOL-BREF (WHOQOL Group, 1998). • Increase in self-esteem (sum score) at T2 compared with T0, as measured by the RSES (Rosenberg, 1965) • Decrease in depressive symptomatology (sum score BDI-II and PHQ-9) at T1 compared to T0. • Mean score of positive treatment expectancy at T0, as measured by the TEX-Q (Alberts et al., 2020) • Frequency of other positive and negative effects (including side effects) of the intervention at time T2, as measured by the PANEPS-I (Baumeister & Moritz, in press) • Presence of other common mental disorders at time T0, assessed by the WSQ (Donker et al., 2009) • Satisfaction of the participants with the program at T2, measured by the ZUF-8 (Schmidt et al., 1989) | — |
Countries
Germany
Contacts
Public ContactSteffen Moritz
Universitätsklinikum Hamburg-Eppendorf, Zentrum für Psychosoziale Medizin, Arbeitsgruppe Klinische Neuropsychologie
Outcome results
None listed